Dataset Information

Applying log-normal peak fitting to parallel reaction monitoring data analysis.

ABSTRACT: To support quantitative data analysis, we have developed a software, peakfit, that fits acquired chromatographic data to the log-normal peak equation and reports the calculated peak parameters. To demonstrate the capabilities of this approach, we provide hereby four example datasets: (1) 15 QCs of a PRM assay targeting the three most common isoforms of Apolipoprotein E (E2, E3, and E4); (2) PRM data of samples with 6 different ApoE phenotypes (E2/2, E2/3, E2/4, E3/3, E3/4, and E4/4); (3) shotgun run of a commercial HeLa digest to demonstrate processing of MS1 data, and (4) a quality control peptide mix to demonstrate assessment of chromatographic performance on basis of the base peak chromatogram.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture, Blood Serum

SUBMITTER: Christoph Stingl

LAB HEAD: Theo M. Luider

PROVIDER: PXD026875 | Pride | 2021-07-26

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	210421OFc1_HeLa_031.raw	Raw
	210421OFc1_HeLa_031__F154475_.mzid.gz	Mzid
	210421OFc1_HeLa_031__F154475_.mzid_210421OFc1_HeLa_031__F154475_.MGF	Mzid
	210421OFc1_PM38_025.raw	Raw
	a166-ApoE-e22.raw	Raw

Items per page:

1 - 5 of 67

Publications

Applying Log-Normal Peak Fitting to Parallel Reaction Monitoring Data Analysis.

Stingl Christoph C Luider Theo M TM

Journal of proteome research 20210714 8

Chromatographic separation is often an important part of mass-spectrometry-based proteomic analysis. It reduces the complexity of the initial samples before they are introduced to mass-spectrometric detection and chromatographic characteristics (such as retention time) add analytical features to the analyte. The acquisition and analysis of chromatographic data are thus of great importance, and specialized software is used for the extraction of quantitative information in an efficient and optimiz ...[more]

PMID: 34260257

Similar Datasets

Project description:Cerebrovascular dysfunction is a hallmark feature of Alzheimer's disease (AD). One of the greatest risk factor for AD is the apolipoprotein E4 (E4) allele. APOE4 genotype has been shown to negatively impact on perivascular amyloid clearance, however, its direct influence along with the other APOE variants (APOE2 and APOE3) on the molecular integrity of the cerebrovasculature has not been largely explored. To address this, we employed a 10-plex tandem isobaric mass tag approach in combination with an ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method, to interrogate unbiased proteomic changes in cerebrovessels from AD and healthy control brains on different APOE genotype backgrounds. We first interrogated changes between healthy control homozygote E2/E2, E3/E3 and E4/E4 cases to identify underlying genotype specific effects on cerebrovessels. EIF2 signaling, regulation of eIF4 and 70S6K signaling and mTOR signaling were the top significantly altered pathways in E4/E4 compared to E3/E3 cases. EIF2, nitric oxide and sirtuin signaling pathways were the top significantly altered pathways in E4/E4 compared to E2/E2 cases. We used a Two-way ANOVA analysis to identify AD-dependent changes and their interactions with APOE genotype. The highest number of significantly regulated proteins from this interaction was observed in E3/E4 (192) and E4/E4 (189) cases. As above, EIF2, mTOR signaling and eIF4 and 70S6K signaling were the top three significantly altered pathways in E4 allele carriers (i.e. E3/E4 and E4/E4 genotypes). Of all the cerebrovascular cell specific markers identified in our proteomic analyses, endothelial cell, astrocyte, and smooth muscle cell specific protein markers were significantly altered in E4/E4 cases, while endothelial cells and astrocyte specific protein markers were altered in E3/E4 cases. These proteomic changes provide novel insights to explain the longstanding link between APOE4 and cerebrovascular dysfunction. The early and converging APOE4 dependent changes we identified could provide novel targets in the cerebrovasculature for developing disease modifying strategies to mitigate the effects of APOE4 genotype on increasing the risk for, and the path towards AD pathogenesis.